-

Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Lucence announced today that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determination (LCD) for the LiquidHALLMARK assay. The LCD covers all nine NCCN guideline-recommended molecular biomarkers in advanced lung cancer patients using LiquidHALLMARK.

LiquidHALLMARK is Lucence’s next-generation sequencing (NGS) liquid biopsy test, which helps oncologists identify biomarkers in advanced cancer patients that may inform their treatment decisions. The policy provides for Medicare reimbursement for LiquidHALLMARK tests furnished to most Medicare fee-for-service patients with lung cancer who meet clinical criteria.

Dr Min-Han Tan, Founding CEO, remarked on the significance of this milestone, saying, “Over 150,000 lung cancer patients over the age of 65 are diagnosed every year in the United States. We are grateful that LiquidHALLMARK will be accessible to more patients in need, and confident that our technology can help inform treatment decisions in the fight against cancer.”

The LiquidHALLMARK test has shown 94.5-100% concordance with tissue-based profiling across nine guideline-recommended biomarkers in the interim results of LIQUIK, a prospective multi-center trial [1]. In this head-to-head study, LiquidHALLMARK identified 24 out of 34 tissue-confirmed guideline-recommended biomarkers, versus 21 by an FDA-approved liquid biopsy test.

[1] Dawar et al. (2022 Oct 20-22). Amplicon-Based Liquid Biopsy Platform Complements Tissue Genotyping in Detection of Guideline-Recommended Biomarkers in Metastatic NSCLC [Poster]. International Society of Liquid Biopsy 4th Annual Congress, Miami, United States.

About Lucence

Lucence is a precision oncology company focused on bringing clarity to cancer care. Our ultrasensitive liquid biopsy tests are based on proprietary AmpliMark™ sequencing technology and data analytics for earlier detection and effective treatment. Lucence operates twin CLIA-licensed, CAP-accredited laboratories in California and Singapore. For more information, visit www.lucence.com.

Contacts

Jack Challis
media@lucence.com

Industry:

Lucence

Release Versions
English

Contacts

Jack Challis
media@lucence.com

More News From Lucence

Lucence Launches LucenceINSIGHT to Detect Cancer Earlier

PALO ALTO, Calif.--(BUSINESS WIRE)--Lucence unveiled LucenceINSIGHT™, its pioneering multi-cancer early detection (MCED) blood test, at their US headquarters. The event was attended by Singapore’s Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation, Singapore (NRF), Mr. Heng Swee Keat. Lucence achieved a significant milestone in February 2023 as the first Asian company to secure Medicare coverage in the US for LiquidHALLMARK, its...

Lucence Presents Data at 2022 World Conference on Lung Cancer (WCLC) Supporting Utility of Amplicon-Based Liquid Biopsy From Detection Through Treatment

VIENNA--(BUSINESS WIRE)--Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment of lung cancer. “Liquid biopsy will continue to transform the way we diagnose, treat, and understand lung cancer,” said Min-Han Tan, Founding CEO and Medical Director at Lucence. “Lucence is committed to leveraging our ultrase...

Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting

CHICAGO--(BUSINESS WIRE)--Lucence, the precision oncology company pioneering ultrasensitive liquid biopsy tests, will present new data on its assays at 2022 ASCO....
Back to Newsroom